Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context

• Main Authors: Karlijn Verkerk (Author), Birgit S. Geurts (Author), Laurien J. Zeverijn (Author), Vincent van der Noort (Author), Henk M.W. Verheul (Author), John B.A.G. Haanen (Author), Astrid A.M. van der Veldt (Author), Ferry A.L.M. Eskens (Author), Maureen J.B. Aarts (Author), Carla M.L. van Herpen (Author), Mathilde Jalving (Author), Jourik A. Gietema (Author), Lot A. Devriese (Author), Mariette Labots (Author), Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (Author), Egbert F. Smit (Author), Haiko J. Bloemendal (Author)
• Format: Book
• Published: Elsevier, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD from PD-1 blocker cemiplimab in patients with loca...